[12] Patent
[11] Patent No.:GC0009462  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2018                56/2018  
Number of the Decision to Grant the Patent:2018/142345
Date of the Decision to Grant the Patent:25/Dec/2018

[21] Application No.:GC 2013-25708

[22] Filing Date:31/10/2013

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
1/11/2012
15/3/2013
61/721,072
61/787,927

[72] Inventors:1- Jonathan A. Hickson،2- Deanna L. Haasch،3- Supriya Gupta،4- Ravi Chari،5- Camellia Zamiri،6- Jijie Gu،7- Dominic J. Ambrosi،8- Susan E. Lappe،9- Yingchun Li،10- Xianhua Cao،11- Louie Naumovski

[73] Owner: AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois , USA

[74] Agent: Abu-Gazaleh Intellectual Property L.L.C

  

 

  

[51]IPC:
Int. Cl.: A61K 31/513, 31/7068, 39/395, 45/06; C07K 16/18, 16/22, 16/28, 16/46 (2006.01)

[56] Cited Documents:

-WO 2012/0613 7 4 A2 (ABBOTT LAB [US] ; GHAYUR TARIQ [US] ; LIU JUNJIAN [US] ; GU JIJIE [US] ; H) 10 May 2012
-US 2011/217237 Al (CHEN MING-JIU [US] ET AL) 8 September 2011
-WO 2011/039370 Al (BOEHRINGER INGELHEIM INT [DE]; BORGES ERIC [DE]; GSCHWIND ANDREAS [DE]) 7 April 2011
 
Examiner: PH. Mohammad S. AlMousa

[54] ANTI-VEGF/DLL4 DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
[57] Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
No. of claims: 10     No. of figures: 1


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.